AtriCure, Inc. (NASDAQ:ATRC) Receives Consensus Rating of “Moderate Buy” from Analysts

AtriCure, Inc. (NASDAQ:ATRC) has been assigned an average rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $48.50.

Several equities research analysts have weighed in on the company. Citigroup restated a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Canaccord Genuity Group raised their price objective on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, UBS Group dropped their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th.

AtriCure Stock Performance

NASDAQ:ATRC opened at $42.95 on Friday. The company has a market cap of $2.18 billion, a price-to-earnings ratio of 204.53 and a beta of 1.20. AtriCure has a fifty-two week low of $25.36 and a fifty-two week high of $43.18. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The stock has a fifty day moving average price of $32.90 and a 200-day moving average price of $31.38.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The business had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the previous year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts anticipate that AtriCure will post 0.2 EPS for the current fiscal year.

Insider Transactions at AtriCure

In related news, Director Sven Wehrwein sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total value of $946,000.00. Following the completion of the transaction, the director owned 40,518 shares in the company, valued at $1,533,201.12. This trade represents a 38.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Justin J. Noznesky sold 6,182 shares of AtriCure stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the sale, the insider owned 100,219 shares in the company, valued at approximately $3,888,497.20. This represents a 5.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 47,246 shares of company stock valued at $1,777,845. 4.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AtriCure

Large investors have recently modified their holdings of the business. Ieq Capital LLC acquired a new position in shares of AtriCure during the second quarter worth $1,161,000. Allworth Financial LP bought a new position in AtriCure during the 2nd quarter worth $43,000. B. Metzler seel. Sohn & Co. AG bought a new position in AtriCure during the 2nd quarter worth $1,396,000. Advisors Capital Management LLC acquired a new position in AtriCure during the 2nd quarter worth about $4,882,000. Finally, Diversify Advisory Services LLC bought a new stake in shares of AtriCure in the 2nd quarter valued at about $448,000. Institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.